Regulatory Oversight and Safety of Probiotic Use

Saccharomyces boulardii probiotics should be used with caution for management of Clostridium difficile infections in hospitalized patients.

[1]  G. Scott,et al.  Dietary Supplement Health and Education Act , 2012 .

[2]  D. Gerding,et al.  Clinical Practice Guidelines for Clostridium difficile Infection in Adults: 2010 Update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA) , 2010, Infection Control & Hospital Epidemiology.

[3]  J. Sanderson,et al.  The mechanisms and efficacy of probiotics in the prevention of Clostridium difficile-associated diarrhoea. , 2009, The Lancet. Infectious diseases.

[4]  Kelly Karpa,et al.  Is there a future for probiotics in preventing Clostridium difficile-associated disease and treatment of recurrent episodes? , 2009, Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition.

[5]  N. Jones,et al.  The use of probiotics in the prevention and treatment of antibiotic-associated diarrhea with special interest in Clostridium difficile-associated diarrhea. , 2009, Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition.

[6]  M. Sanders.  How Do We Know When Something Called "Probiotic" Is Really a Probiotic? A Guideline for Consumers and Health Care Professionals , 2009 .

[7]  C. Surawicz.  Role of Probiotics in Antibiotic-associated Diarrhea, Clostridium difficile-associated Diarrhea, and Recurrent Clostridium difficile-associated Diarrhea , 2008, Journal of clinical gastroenterology.

[8]  Andreas Günther,et al.  Relatedness of medically important strains of Saccharomyces cerevisiae as revealed by phylogenetics and metabolomics , 2008, Yeast.

[9]  M. Sanders,et al.  Probiotics and prebiotics in dietetics practice. , 2008, Journal of the American Dietetic Association.

[10]  J. Heimbach.  Health-benefit claims for probiotic products. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  L. Saldanha.  US Food and Drug Administration regulations governing label claims for food products, including probiotics. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[12]  M. Segarra-Newnham,et al.  Probiotics for Clostridium difficile–Associated Diarrhea: Focus on Lactobacillus rhamnosus GG and Saccharomyces boulardii , 2007, The Annals of pharmacotherapy.

[13]  J. Klotter.  Dietary Supplement and Nonprescription Drug Consumer Protection Act , 2007 .

[14]  V. Frankos,et al.  Current good manufacturing practice in manufacturing, packaging, labeling, or holding operations for dietary supplements. Final rule. , 2007, Federal register.

[15]  L. Mcfarland.  Meta-Analysis of Probiotics for the Prevention of Antibiotic Associated Diarrhea and the Treatment of Clostridium difficile Disease , 2006, The American Journal of Gastroenterology.

[16]  Christophe Hennequin,et al.  Invasive Saccharomyces infection: a comprehensive review. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[17]  D. Musher,et al.  Treatment of Clostridium difficile-associated disease: old therapies and new strategies. , 2005, The Lancet. Infectious diseases.

[18]  Patricia Muñoz,et al.  Saccharomyces cerevisiae fungemia: an emerging infectious disease. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[19]  L. Mcfarland.  Alternative treatments for Clostridium difficile disease: what really works? , 2005, Journal of medical microbiology.

[20]  C. Surawicz,et al.  The search for a better treatment for recurrent Clostridium difficile disease: use of high-dose vancomycin combined with Saccharomyces boulardii. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[21]  J. Jacquemin,et al.  Possible Role of Catheters in Saccharomyces boulardii Fungemia , 2000, European Journal of Clinical Microbiology and Infectious Diseases.

[22]  Regulations on statements made for dietary supplements concerning the effect of the product on the structure or function of the body. Food and Drug Administration, HHS. Final rule. , 2000, Federal register.

[23]  A. L. Young,et al.  The Dietary Supplement Health and Education Act. , 1995, Food and drug law journal.

[24]  Friedman Ga,et al.  Federal food, drug and cosmetic act. , 1955 .